Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Foxo Technologies Inc (A:FOXO)

Business Focus: IT Services & Consulting

Sector:  Technology Industry:  IT Services & Consulting
See Regulatory Filings on SEC
Company Contact
Address: 729 Washington Ave. N, Suite 600
Tel: 1-949-5743860
IR: See website
Key People
Mark K. White
Interim Chief Executive Officer, Director
Martin C. Ward
Interim Chief Financial Officer
Business Overview
FOXO Technologies Inc. is a biotechnology company. The Company is focused on commercializing longevity science through products and services that serve the life insurance industry. Its epigenetic technology applies artificial intelligence (AI) to deoxyribonucleic acid (DNA) methylation to identify molecular biomarkers of human health and aging. The Company operates through two segments: FOXO Labs and FOXO Life. FOXO Labs is commercializing epigenetic biomarker technology to be used for mortality underwriting and risk classification in the global life insurance industry. Its biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment. FOXO Life is redefining the relationship between consumers and insurers by combining life insurance with healthy longevity. FOXO Life seeks to transform the value proposition of the life insurance carrier from a provider of mortality risk protection products.
Financial Overview
For the fiscal year ended 31 December 2023, Foxo Technologies Inc revenues decreased 72% to $145K. Net loss applicable to common stockholders decreased 69% to $29.8M. Revenues reflect FOXO Labs segment decrease of 74% to $126K, FOXO Life segment decrease of 32% to $19K. Lower net loss reflects Non-cash change in fair value of convert decrease from $28.2M (expense) to $0K, Change in fair value of forward purchase decrease from $27.3M (expense) to $0K.